ArticleEmerging infectious diseases2022
Sensitivity of Mycobacterium leprae to Telacebec.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the risk of dapsone hypersensitivity syndrome in Nepalese Leprosy Patients via HLA-B* 13:01 screening using real-time PCR and comparative meta-analysis of international data.PLoS neglected tropical diseases · 2026Pooled it
- Inhibitors of cytochromemBio · 2026Article
- The Mycobacterium abscessus cytochrome bcc:aaNature communications · 2026Article
- A Series of Pyrazolo-Quinazoline Amines Inhibits the CytochromeJournal of medicinal chemistry · 2026Article
- The role of cytochrome bcNature communications · 2025Article
- Assessment of TB47 as a potential novel therapeutic agent:Antimicrobial agents and chemotherapy · 2025Article
- Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Unprecedented in vivo activity of telacebec against Mycobacterium leprae.PLoS neglected tropical diseases · 2025Article
- Leprosy research updates: Shaping the future of global health.The Indian journal of medical research · 2025Article
- Leprosy.Nature reviews. Disease primers · 2024Review
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- Unlocking Opportunities forACS infectious diseases · 2024Review
- Whole mitogenome sequencing uncovers a relation between mitochondrial heteroplasmy and leprosy severity.Human genomics · 2023Article
- The Many Hosts of Mycobacteria 9 (MHM9): A conference report.Tuberculosis (Edinburgh, Scotland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.